JavaScript is disabled in your browser. Please enable JavaScript to view this website.
AB110650

Anti-CTLA4 antibody [KT56]

Be the first to review this product! Submit a review

|

(1 Publication)

Mouse Monoclonal CTLA4 antibody. Suitable for sELISA and reacts with Recombinant full length protein - Human samples. Cited in 1 publication. Immunogen corresponding to Recombinant Full Length Protein corresponding to Human CTLA4.

View Alternative Names

CD152, CTLA4, Cytotoxic T-lymphocyte protein 4, Cytotoxic T-lymphocyte-associated antigen 4, CTLA-4

1 Images
Sandwich ELISA - Anti-CTLA4 antibody [KT56] (AB110650)
  • sELISA

Unknown

Sandwich ELISA - Anti-CTLA4 antibody [KT56] (AB110650)

Sandwich ELISA using ab110650 coated plate and HRP conjugated ab106490 for detection.

Key facts

Host species

Mouse

Clonality

Monoclonal

Clone number

KT56

Isotype

IgG1

Carrier free

No

Reacts with

Human

Applications

sELISA

applications

Immunogen

Recombinant Full Length Protein corresponding to Human CTLA4.

P16410

Reactivity data

{ "title": "Reactivity Data", "filters": { "stats": ["", "Species", "Dilution Info", "Notes"], "tabs": { "all-applications": {"fullname" : "All Applications", "shortname": "All Applications"}, "sELISA" : {"fullname" : "Sandwich ELISA", "shortname":"sELISA"} }, "product-promise": { "all": "all", "testedAndGuaranteed": "tested", "guaranteed": "expected", "predicted": "predicted", "notRecommended": "not-recommended" } }, "values": { "Human": { "sELISA-species-checked": "predicted", "sELISA-species-dilution-info": "", "sELISA-species-notes": "" }, "Recombinant full length protein - Human": { "sELISA-species-checked": "testedAndGuaranteed", "sELISA-species-dilution-info": "5 µg/mL", "sELISA-species-notes": "<p>as the dectection antibody.</p>" } } }

Properties and storage information

Form
Liquid
Purification technique
Affinity purification Protein A
Storage buffer
Preservative: 0.01% Thimerosal (merthiolate) Constituents: PBS
Shipped at conditions
Blue Ice
Appropriate short-term storage duration
1-2 weeks
Appropriate short-term storage conditions
+4°C
Appropriate long-term storage conditions
-20°C
Aliquoting information
Upon delivery aliquot
Storage information
Avoid freeze / thaw cycle

Supplementary information

This supplementary information is collated from multiple sources and compiled automatically.

CTLA-4 also known as CD152 is an immune checkpoint receptor with a molecular weight of approximately 34 kDa. This protein is expressed on the surface of T-cells especially after activation and sometimes on regulatory T-cells (Tregs). CTLA-4 competes with CD28 for binding to the same ligands CD80 and CD86 on antigen-presenting cells. Unlike CD28 which stimulates T-cell activation CTLA-4 sends inhibitory signals to downregulate immune responses. By doing this CTLA-4 helps maintain immune system homeostasis and prevents autoimmune reactions.
Biological function summary

The CTLA-4 protein functions as a critical regulator of the immune system. It interacts with CD80/CD86 in a complex that effectively transmits inhibitory signals to T-cells. CTLA-4 controls the amplitude of the initial activation of T-cells ensuring that the body's immune responses are kept under control. In regulatory T-cells CTLA-4 engagement contributes to their immunosuppressive functions through which they maintain tolerance to self-antigens and prevent overactive immune reactions.

Pathways

CTLA-4 involves itself in the adaptive immune response pathways specifically the regulation of T-cell activity. CTLA-4's interaction with CD80/CD86 modulates pathways associated with TCR (T-cell receptor) signaling. When CTLA-4 binds its ligands it recruits phosphatases such as SHP-2 that dephosphorylate signaling proteins leading to the downregulation of T-cell interaction. This pathway interaction exemplifies how CTLA-4 acts in concert with proteins like CD28 to finely tune immune responses.

CTLA-4 plays a role in autoimmune diseases and cancer. The dysregulation of CTLA-4 function can lead to autoimmune disorders where the immune system attacks the body's own tissue. In cancer tumor cells may manipulate CTLA-4 pathways to evade immune surveillance. Targeted therapies like anti-CTLA-4 antibodies such as ipilimumab have been developed to block CTLA-4 aiming to enhance the immune system’s ability to attack cancer cells. These treatments highlight the role of CTLA-4 in balancing immune activity and the potential to alter this balance for therapeutic benefit.

Product protocols

For this product, it's our understanding that no specific protocols are required. You can visit:

Target data

Inhibitory receptor acting as a major negative regulator of T-cell responses. The affinity of CTLA4 for its natural B7 family ligands, CD80 and CD86, is considerably stronger than the affinity of their cognate stimulatory coreceptor CD28.
See full target information CTLA4

Publications (1)

Recent publications for all applications. Explore the full list and refine your search

Oncology reports 44:43-54 PubMed32319655

2020

TIRC7 inhibits Th1 cells by upregulating the expression of CTLA‑4 and STAT3 in mice with acute graft‑versus‑host disease.

Applications

Unspecified application

Species

Unspecified reactive species

Feng Zhu,Tingting Qiu,Shengyun Zhu,Kai Zhao,Chong Chen,Jianlin Qiao,Bin Pan,Zhiling Yan,Wei Chen,Qiong Liu,Qingyun Wu,Jiang Cao,Wei Sang,Lingyu Zeng,Haiying Sun,Zhenyu Li,Kailin Xu
View all publications

Product promise

We are committed to supporting your work with high-quality reagents, and we're here for you every step of the way. In the unlikely event that one of our products does not perform as expected, you're protected by our Product Promise.
For full details, please see our Terms & Conditions

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.

For licensing inquiries, please contact partnerships@abcam.com